ArticleBritish journal of cancer2026
Unlocking the clock: a systematic review and meta-analysis on optimizing immune checkpoint inhibitor timing for advanced solid tumors.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence from observational studies suggests that the time-of-day of immune checkpoint inhibitor (ICI) infusion may influence efficacy. This study sought to quantitatively evaluate the impact of ICI infusion timing on the outcomes of patients with solid tumors through a systematic review and meta-analysis.
methodsWe systematically searched Embase, PubMed, and Scopus for articles published before April 1, 2026, that compared the efficacy outcomes between early and late time-of-day ICI administration. The primary endpoints were overall survival and progression-free survival. The secondary outcomes included objective response rates and immune-related adverse events. Hazard and risk ratios were pooled using the random-effects model.
resultsForty-three retrospective cohort studies involving 11,941 patients were included. Pooled analysis revealed a significant association between early time-of-day infusion and improved OS (HR = 0.60, 95% CI: 0.53-0.67) and PFS (HR = 0.65, 95% CI: 0.57-0.73). ORR was also higher (RR = 1.37, 95% CI: 1.21-1.54). No significant differences were observed for any-grade irAEs (RR = 0.98, 95% CI: 0.73-1.32) or grade ≥3 irAEs (RR = 0.95, 95% CI: 0.62-1.46). However, significant publication bias was detected (Egger's test, p < 0.001); after trim-and-fill adjustment, the OS association remained significant (adjusted HR = 0.79, 95% CI: 0.71-0.89), whereas PFS was attenuated and its confidence interval reached the null boundary after rounding (adjusted HR = 0.89, 95% CI: 0.79-1.00).
conclusionsThis meta-analysis suggests significant association between early time-of-day ICI administration and improved efficacy outcomes. These findings must be interpreted with caution, as the evidence base is composed entirely of observational studies with inherent risks of bias, and the presence of publication bias may have led to an overestimation of the observed effect size. While current evidence is insufficient to warrant an immediate change in clinical practice, it provides a compelling rationale for the design of future prospective trials to validate these findings.
Identifiers
42736417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.